Annovis Bio, Inc. (ANVS) stock
Close on Nov 11, 2026Market cap $36.36MP/E –Yield –
Annovis Bio, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $36.36M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $36.36M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$49.52M
- EPS, diluted
- -$1.78
- Book value per share
- -$0.11
- Diluted shares
- 38M
Trading
- Next earnings
- Mar 15, 2027 (estimated, after the close)
- Previous close
- $0.87
- Open
- $0.87
- Day's range
- $0.79 – $0.87
- Volume
- 1,619,198
- Average volume (20 days)
- 3,273,919
- Beta (5 years)
- 1.93
- 52-week range
- $0.62 – $5.50
- RSI (14 days)
- 41.1
- Volatility (1 year)
- 103.9%
- Relative volume
- 1.14×
- WACC
- 14.5%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANVS | S&P 500 | Difference | ANVS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -29.5% | -2.4% | −27.1 pts | ||
| 3 months | -54.9% | -1.2% | −53.7 pts | ||
| Year to date | -75.3% | +12.3% | −87.6 pts | ||
| 1 year | -59.6% | +12.4% | −72.0 pts | ||
| 3 years | -85.3% | +78.8% | −164.1 pts | -47.2% | +21.4% |
| 5 years | -97.4% | +75.2% | −172.5 pts | -51.7% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Annovis Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- News
- Update
About Annovis Bio
Pharmaceutical Preparations
Annovis Bio is a late-stage clinical drug platform company that discovers and develops therapeutics targeting neurodegenerative conditions, primarily Alzheimer’s disease and Parkinson’s disease. The company's lead drug candidate is buntanetap, an orally administered, brain-penetrant small molecule designed to inhibit the synthesis of neurotoxic aggregating proteins that disrupt nerve cell communication. Its clinical pipeline also features ANVS405, an intravenous formulation targeting acute indications such as traumatic brain injury and stroke, and ANVS301, an oral compound focused on advanced Alzheimer’s disease. As a clinical-stage biotechnology firm, the company directs its investigative treatments toward patients suffering from chronic and acute neurodegenerative disorders.
Company profile, executives and historyAnnovis Bio stock: common questions
What is Annovis Bio's stock price?
ANVS closed at $0.85 on Nov 11, 2026, down 2.40% on the day. Over the past 52 weeks it traded between $0.62 and $5.50.
What is Annovis Bio's market cap?
Annovis Bio was worth $36.36M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ANVS's P/E ratio?
Annovis Bio lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.78), so it has no meaningful P/E ratio.
How much revenue does Annovis Bio make?
Annovis Bio reported revenue of $0 for the twelve months to Jun 30, 2026.
Does Annovis Bio pay a dividend?
No. Annovis Bio has not paid a cash dividend over the last twelve months.
When does Annovis Bio report earnings next?
Annovis Bio is expected to report Q4 FY2026 results on Mar 15, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ANVS stock performed over the past year?
Including dividends, ANVS returned -59.6% over the past year, against +12.4% for the S&P 500.
How many ANVS shares are sold short?
5M shares were sold short at the latest FINRA report, 16.34% of the float, or 6.8 days of average trading volume.
Who are Annovis Bio's competitors?
Companies most similar to Annovis Bio by business, industry and size include ACIU, BIVI, CRVO, ANRO, PMN.
See a number that looks wrong?